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ABSTRACT
Aims: The purpose of this study was to identify whether NHS Trusts where 
discrimination in the delivery of care to patients from the South Asian community 
had been demonstrated had taken any actions to address the issue over the 
subsequent year.
Methods: Freedom of information requests were sent to three trusts which had 
provided evidence of disparate provision of biologic therapy to patients with 
Crohn’s disease, their associated Clinical Commissioning Groups and HealthWatch 
organisations to seek evidence they had remedied the situation. Requests were 
also sent to the Care Quality Commission, NHS Improvement and the Equality 
and Human Rights Commission seeking examples where they had responded to 
inequitable delivery of care related to ethnicity.
Results: No organisation had any evidence of responses to the situation, many 
unable to accept its existence. 
Conclusion: Legal duties are discussed and the only remedy appears to be through 
the tort of negligence.
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INTRODUCTION
Crohn’s disease and ulcerative colitis are both chronic incurable inflammatory 
bowel diseases characterised by diarrhoea and abdominal pain. During the last 
two decades, these diseases have increased significantly in frequency and spread 
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DOES THE FAILURE TO PROVIDE EQUITABLE ACCESS TO TREATMENT 
LEAD TO ACTION BY NHS ORGANISATIONS? 
throughout the world.1 Studies on migrant communities have shown them to be 
particularly susceptible to aggressive forms of chronic incurable inflammatory 
bowel disease, especially in the second generation.2,3 Their cause is unknown and 
so treatment is directed at control of symptoms rather than cure. Up until the end 
of the twentieth century, this treatment was limited to a small range of drugs or 
surgery. The drugs were low cost and surgery could involve significant resections 
of the bowel and also the formation of a permanent stoma. Both conditions also 
significantly increase the risk of developing colonic cancer.4,5 However, during the 
last decade there have been significant changes in the management of both Crohn’s 
disease and ulcerative colitis with the introduction of monoclonal antibodies. 
These treatments are expensive, costing between £12,000 and £15,000 per year for 
the medications alone. Their use is approved by the National Institute for Health 
and Care Excellence (NICE)6,7 and this has had significant economic consequenc-
es for hospital trusts and Clinical Commissioning Groups (CCGs). The provision 
of these agents is regulated by a Technology Appraisal Guidance, which means 
that if they are indicated they must be provided to patients. The purpose of Tech-
nology Appraisal Guidance is ‘to ensure that all NHS patients have equitable 
access to the most clinically- and cost-effective treatments that are available’.8
1 SC Ng, HY Shi, N Hamidi, FE Underwood, et al., ‘Worldwide Incidence and Prevalence 
of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-
Based Studies’ (2018) 390 Lancet 2769.
2 I Carr and JF Mayberry, ‘The Effects of Migration on Ulcerative Colitis: A Three-Year 
Prospective Study among Europeans and First- and Second-Generation South Asians in 
Leicester (1991–1994)’ (1999) 94 American Journal of Gastroenterology 2918.
3 A Farrukh and JF Mayberry, ‘Inflammatory Bowel Disease and the South Asian 
Diaspora’ (2019) JGH Open <https://doi.org/10.1002/jgh3.12149 > accessed 6 August 
2019.
4 JA Eaden, KR Abrams and JF Mayberry, ‘The Risk of Colorectal Cancer in Ulcerative 
Colitis: A Meta-Analysis’ (2001) 48 Gut 526.
5 C Canavan, KR Abrams and J Mayberry, ‘Meta-Analysis: Colorectal and Small Bowel 
Cancer Risk in Patients with Crohn’s Disease’ (2006) 23 Alimentary Pharmacology and 
Therapeutics 1097.
6 NICE, ‘Infliximab and Aalumimab for the Treatment of Crohn’s disease’ (NICE, 2010) 
<nice.org.uk/guidance/ta187> accessed 14 May 2019.
7 NICE, ‘Infliximab, Adalumimab and Golumimab for Treating Moderately to Severely 
Active Ulcerative Colitis after the Failure of Conventional Therapy’ (NICE, 2015) <nice.
org.uk/guidance/ta329> accessed 22 November 2016.
8 NICE, ‘Summary of Technology Appraisal Decisions’ (NICE, 2016) <nice.org.uk/
about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/
summary-of-decisions> accessed 22 November 2016.
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Discrimination in the delivery of care has long been recognised in the United 
States, but during the last 20 years it has become apparent that this is also true in 
the United Kingdom.9 Recent studies have highlighted evidence that South Asian 
patients have less access to these medications.10 A study in Leicester demonstrated 
that South Asian patients with Crohn’s disease were four times less likely to 
receive biologic therapy than their English counterparts.11 This difference was 
independent of gender and accounted for age differences between the two 
communities. A subsequent study looked at the provision of biologic therapy for 
Crohn’s disease in 10 English NHS Trusts, which served areas with the largest 
ethnic variation.12 The Freedom of Information (FOI) request revealed that in 
three trusts, Pennine Acute Hospitals NHS Trust covering Oldham and North 
Manchester, Barking, Havering & Redbridge University Hospitals NHS Trust and 
University Hospitals of Leicester NHS Trust, South Asian patients with Crohn’s 
disease were significantly less likely to receive biologic therapy than English 
patients. One trust, Bradford Teaching Hospitals NHS Foundation Trust, declined 
to provide information on the basis that it did not collect data on ethnicity. In the 
remaining trusts there was no evidence of minority populations being underserved. 
In ulcerative colitis a review of the management of patients over the decade 
following their initial diagnosis showed that South Asian patients were less likely 
to be seen by a consultant, less likely to be investigated and more likely to be 
discharged from hospital based care.13 There is supportive evidence for such 
findings from the United States, where discrimination in the delivery of care to 
ethnic minorities has been long recognised.14 In the 1990s the American Medical 
9 NICE (n 8).
10 A Farrukh and J Mayberry, ‘Ethnic Variations in the Provision of Biologic Therapy for 
Crohn’s Disease: A Freedom of Information Study’ (2015) 83 Medico-Legal Journal 104; 
A Farrukh and JF Mayberry, ‘Apparent Discrimination in the Provision of Biologic 
Therapy to Patients with Crohn’s Disease According to Ethnicity’ (2015) 129 Public 
Health 460; A Farrukh and JF Mayberry, ‘Patients with Ulcerative Colitis from Diverse 
Populations: The Leicester Experience’ (2016) 84 Medico Legal Journal 31; A Farrukh 
and JF Mayberry, ‘Evidences of Differences and Discrimination in the Delivery of Care: 
Colorectal Screening in Healthy People and in the Care and Surveillance of Patients with 
Inflammatory Bowel Disease’ (2019) 1 Gastrointestinal Disorders 253.
11 Farrukh and Mayberry (n 12).
12 Ibid.
13 Farrukh and Mayberry (n 12).
14 JF Jackson III, T Dhere, A Repaka, A Shaukat and S Sitaraman, ‘Crohn’s Disease in an 
African-American Population’ (2008) 336 American Journal of Medical Sciences 389; 
MH Flasar, T Johnson, MC Roghmann and RK Cross, ‘Disparities in the Use of 
Immunomodulators and Biologics for the Treatment of Inflammatory Bowel Disease: A 
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Association recognised that ‘subconscious bias’ may be a factor for such clinical 
practice.15 In the United States, Geiger has attributed such differences in care to 
either ‘conscious bias or, more often, unconscious negative stereotyping’16. There 
are no other ready explanations for such differences in the care of patients with 
inflammatory bowel disease in the United Kingdom. The diseases occur with 
equal severity in patients of South Asian and English origin, and the studies 
discussed above compensated for differences in age structure between 
communities, indicating that the differences in standards of care are real.
The three trusts where patients received disparate care were informed of the 
results through a range of methods including presentations and publications. The 
purpose of this study was to investigate the practical responses of Pennine Acute 
Hospitals NHS Trust, Barking, Havering & Redbridge University Hospitals NHS 
Trust and University Hospitals of Leicester NHS Trust, to these findings one year 
later. Related organisations concerned with the delivery of care by these trusts 
were also contacted to assess what action they had taken. These organisations fell 
into two groups, namely local and national. Local groups included the Clinical 
Commissioning Groups (CCGs) and the Health and Well-Being Boards, while 
national organisations contacted were the Care Quality Commission, NHS 
Improvement and the Equality and Human Rights Commission. CCGs are 
clinically led statutory NHS bodies responsible for the planning and commissioning 
of health care services for their local area. Health and Well-Being Boards 
commission local HealthWatch organisations. They are a statutory service set up 
by local councils as part of the Health and Social Care Act 2012. HealthWatch 
describes its role as:
… the independent national champion for people who use health and social 
care services. We’re here to make sure that those running services, and the 
government, put people at the heart of care.17
Retrospective Cohort Study’ (2008) 14 Inflammatory Bowel Disease 13; OM Damas, DA 
Jahann, R Reznik, JL McCauley, L Tamariz, AR Deshpande, MT Abreu and DA Sussman, 
‘Phenotypic Manifestations of Inflammatory Bowel Disease Differ between Hispanics 
and Non-Hispanic Whites: Results of a Large Cohort Study’ (2013) 108 American Journal 
of Gastroenterology 231.
15 Council on Ethical and Judicial Affairs American Medical Association, ‘Black-White 
Disparities in Health Care’ (1990) 263 Journal of the American Medical Association 2344.
16 HJ Geiger, ‘Racial and Ethnic Disparities in Diagnosis and Treatment: A Review of the 
Evidence and Consideration of Causes’ (2003) in BD Smedley, AY Stith and AR Nelson 
(eds), Unequal Treatment Confronting Racial and Ethnic Disparities in Healthcare (The 
National Academies Press Washington 2003).
17 HealthWatch (2019) <healthwatch.co.uk/what-we-do> accessed 13 May/2019.
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Each trust is linked with several CCGs and HealthWatch groups, representing 
different areas which they serve.
The method adopted in this study was to approach each of the three trusts 
where there was evidence of underserving members of the ethnic minority 
community who had inflammatory bowel disease. In addition those bodies 
who have a statutory duty to monitor their delivery of service were also 
approached. On a local basis this was the CCGs and HealthWatch organisations 
and nationally CQC, NHS Improvement and EHRC. The technique chosen 
was to submit a Freedom of Information (FOI) request, as this allowed 
follow-up questions, when answers lacked clarity. Some authors have expressed 
the hope that greater transparency in health care will lead to improved services 
and that FOIs could be one engine for such a change.18 However, the 
effectiveness of FOI ultimately depends upon the attitude and commitment 
with which it is approached by government agencies and their staff as well as 
public insistence that the statute is implemented in a way which fulfils its 
purpose.19
STUDY
In this study FOI requests were sent to:
1. The three NHS Trusts which had treated fewer South Asian patients than 
expected, namely Pennine Acute Hospitals NHS Trust, Barking, Havering & 
Redbridge University Hospitals NHS Trust and University Hospitals of 
Leicester NHS Trust
2. The Clinical Commissioning Groups (CCGs) and HealthWatch groups 
commissioned by Health and Wellbeing Boards associated with these three 
Trusts
3. Care Quality Commission (CQC)
4. NHS Improvement (formerly Monitor)
5. Equality and Human Rights Commission (EHRCC)
18 AJ Fowler, RA Agha RA, CF Camm and P Littlejohns, ‘The UK Freedom of 
Information Act (2000) in Healthcare Research: A Systematic Review’ (2013) BMJ Open 
<10.1136/bmjopen-2013-002967> accessed 6 August 2019.
19 M Berger, ‘The Freedom of Information Act: Implications for Public Health Policy and 
Practice’ (2011) 126 Public Health Reports 428.
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NHS Trusts, CCGs and HealthWatch groups were asked to respond to two ques-
tions related to the information and published work on disparate care. They were:
1. What actions have the Trust/CCG//HealthWatch taken to ensure equitable 
access by the South Asian community and other minority groups to treatment 
with biologics for inflammatory bowel disease?
2. What monitoring systems does the Trust/CCG/HealthWatch have in place to 
ensure equitable access to treatment with biologics by patients from the South 
Asian community and other minority groups?
Groups which failed to reply were sent a further request. Where answers were 
unclear or ambiguous explanations were sought.
The CQC, NHS Improvement and the EHRC were asked:
‘Can you provide a list of the interventions that the CQC/Monitor or NHS 
Improvement/EHRC have made when there has been evidence of discrimination 
in the delivery of care to patients in the NHS based on ethnicity?’
Again where answers were unclear or appeared evasive respondents were 
asked to expand or clarify their response.
Responses were reviewed for common themes using content analysis.20 This 
technique has previously been used in data drawn from multiple sources, including 
relatively short extracts.21
Responses were received from the three NHS Trusts, six CCGs but only one 
HealthWatch. Those 10 organisations which replied provided answers to all of the 
questions posed to them. Many of the responses from different organisations 
across the country were carbon copies of each other, raising the possibility that 
Freedom of Information requests are responded to with standard answers and 
hence the need to seek clarification in some cases. The common themes identified 
from responses were:
1. There is no discrimination in the delivery of care and we deliver clinically 
appropriate treatment to all patients. This theme was present in responses from 
all 10 organisations.
20 GW Ryan and HR Bernard, ‘Techniques to Identify Themes’ (2003) 15 Field Methods 
85; K Krippendorff, Content Analysis: An Introduction to Its Methodology (2nd edn, 
2004 Sage).
21 JF Mayberry, ‘An Analysis of Blogs from Medical Students on “English Parallel” 
Courses in Central and Eastern Europe’ (2013) 81 Medico Legal Journal 171.
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2. There is no mechanism for routine monitoring whether there is any 
discrimination in the delivery of care. The data we collect on treatment and 
ethnicity is too large to allow any analysis. This theme was seen in responses 
from all NHS Trusts and CCGs
3. The organisation depends upon complaints about discrimination to initiate 
action and it has not received any. This theme was identified in the response 
from the HealthWatch organisation.
Examples of responses to Question 1 included:
‘We can confirm that all our patients are treated without discrimination’.
‘It would be both difficult and unlikely for there not to be equitable access 
to biologic therapy’.
‘The Trust only starts patients on biologics according to strict clinical 
criteria’.
No trust had responded to the published findings based on evidence they had 
supplied through earlier Freedom of Information requests.
Answers to Question 2 included:
‘It is not considered that there is an access issue within name of organisation’.
CCGs stated they were unable to access relevant data. However, if they became 
aware that:
access is especially focussed on or restricted amongst particular ethnic groups, 
then the CCGs would take this issue very seriously and issue a Contract 
Performance Notice.
The need to monitor equality of access to care is a specific requirement of contracts 
between CCGs and Trusts and is an obligation on both organisations. The second 
question addressed this requirement. None of the respondents had any monitoring 
system in place. Indeed, most organisations tacitly recognised that monitoring equality 
in delivery of care did not occur. HealthWatch Oldham replied that it had:
a number of systems in place for monitoring Oldham residents’ access to and 
experience of health and social care services. These include a broad survey of 
patient experiences as well as using information from NHS Choices, Patient 
Opinion and the Care Quality Commission.
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The common themes reported by CQC and NHS Improvement included:
1. The information cannot be readily accessed from our data collection.
2. It is not within our Terms of Reference; some other body is responsible.
The CQC reported that it would not issue a warning notice for the scenario 
described in the question as such notices are only used for systemic failures. It 
went on to state that enforcement actions were on the basis of contravention of 
Regulations 9, 10 and 17 of the Health and Social Care Act 2008 (Regulated 
Activities) Regulations 2014. To determine whether breaches of these regulations 
related to disparity in delivery of care based on ethnicity each action would need 
to be manually reviewed and the CQC was unwilling to conduct such an exercise. 
Regulation 9 states:
1. The care and treatment of service users must—
a. be appropriate,
b. meet their needs; and
c. reflect their preferences.
2. Without limiting paragraph (1), the things which a registered person must do 
to comply with that paragraph include—
a. carrying out, collaboratively with the relevant person, an assessment of the 
needs and preferences for care and treatment of the service user;
b. designing care or treatment with a view to achieving service users’ 
preferences and ensuring their needs are met.
and Regulation 17:
2(e) seek and act on feedback from relevant persons and other persons on the 
services provided in the carrying on of the regulated activity, for the purposes 
of continually evaluating and improving such services.
Clearly the underserving of ethnic minorities by Trusts falls within these 
categories and it is of concern that the CQC did not consider that this represented 
a systems failure and falls clearly within the grounds for issuing a warning notice. 
The failure of the CQC to deal with underperformance in a trust has previously 
been identified in a report by Grant Thornton on University Hospital of Morecombe 
Bay where it concluded that there had, on the balance of probabilities, been ‘an 
attempt to cover-up matters concerning CQC’s regulation of UHMB’.22
22 Grant Thornton, ‘The Care Quality Commission re: Project Ambrose dated 14 June 
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NHS Improvement’s response was that it held some logs of its work but they:
do not go into sufficient granularity to specify whether any of those actions 
were based on any concerns relating to discrimination based on ethnicity. 
Please note that NHS Improvement does not have a role in monitoring trusts’ 
compliance with equalities legislation.
This is despite the fact that from 2014 it was tasked with issuing NHS Provider 
Licences to Trusts providing clinical care. Among the conditions for licenses were:
4 (a) improving the quality of health care services provided for the purposes of 
the NHS (…) or the efficiency of their provision, (b) reducing inequalities 
between persons with respect to their ability to access those services, and (c) 
reducing inequalities between persons with respect to the outcomes achieved 
for them by the provision of those services.23
The EHRC considered such issues did fall within its Terms of Reference but 
reported that:
Following a search of the Commission’s Section 30 intervention records, we 
have determined that we hold no information relevant to your request.
DISCUSSION
Trusts and their associated bodies are unwilling to accept that there is discrimina-
tion in the delivery of care, despite the fact that this has been shown through inde-
pendent analysis of their own data. Although they have collected these data they 
consider them too large to allow any analysis and have no structures in place to 
monitor whether they are delivering an equitable service. Rather they depend upon 
external complaints by patients about discrimination being made to them, and 
they deny having received any. In addition, there is no evidence that any NHS 
Trust or CCG where there was disparate care in delivery of biologics has taken any 
action to remedy the situation.
2013’ <cqc.org.uk/sites/default/files/media/documents/grant_thornton_uk_llp_morecambe_ 
bay.pdf> accessed 13 May 2019.
23 Monitor, ‘The New NHS Provider Licence’ (2013) <gov.uk/government/uploads/
system/uploads/attachment_data/file/285008/ToPublishLicenceDoc14February.pdf> 
accessed 1 December 2016.
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There Is No Discrimination in the Delivery of Care
Despite the responses from the three NHS trusts and their associated CCGs prob-
lems with the equitable delivery of care in the secondary sector are widespread. 
The situation demonstrated for South Asian patients with inflammatory bowel 
disease is not unusual. Other examples include Black African women with breast 
cancer being less likely to have surgery and more likely to be simply offered 
chemotherapy, while Pakistani women were less likely to be offered radiotherapy 
or hormone treatment than White women.24 In the twenty-first century ethnic 
minority patients on the renal transplant register are still less likely to receive a 
donor organ than White patients.25 In the field of mental health Black service 
users tend to be given injectable depot treatments rather than offered tablets or 
cognitive behavioural therapy.26 Further examples include a qualitative study of 
registered nurses working in hospitals in Leeds which identified racism affecting 
their care of Pakistani patients.27 Earlier a group of South Asian inpatients had 
described how they felt that they needed to fit into what they described as an 
‘English place’.28 In another study from Middlesborough, only 5% of Pakistani 
patients were told of the availability of professional translators to help with 
consultations.29
24 RH Jack, EA Davies and H Møller, ‘Breast Cancer Incidence, Stage, Treatment and 
Survival in Ethnic Groups in South East England’ (2009) 100 British Journal of Cancer 
545.
25 U Udavaraj, R Pruthi, A Casula and P Roderick, ‘UK Renal Registry 16th 
Annual Report: Chapter 6 Demographics and Outcomes of Patients from Different Ethnic 
Groups on Renal Replacement Therapy in the UK’ (2013) 125 Nephron Clinical 
Practice 111.
26 J Das-Munshi, D Bhugra and MJ Crawford, ‘Ethnic Minority Inequalities in Access to 
Treatments for Schizophrenia and Schizoaffective Disorders: Findings from a Nationally 
Representative Cross-Sectional Study’ (2018) 16 BMC Medicine 55.
27 JD Cortis, ‘Meeting the Needs of Minority Ethnic Patients’ (2004) 48 Journal of 
Advanced Nursing 51.
28 V Vydelingum, ‘South Asian Patients’ Lived Experience of Acute Care in an English 
Hospital: A Phenomenological Study’ (2000) 32 Journal of Advanced Nursing 100.
29 R Madhok, A Hameed and R Bhopal, ‘Satisfaction with Health Services among the 
Pakistani Population in Middlesborough, England’ (1998) 20 Journal of Public Health 
Medicine 295.
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There Is No Mechanism for Routine Monitoring for Discrimination in the 
Delivery of Care
The Equality Impact Analysis for the NHS for 2016 and for 2017–2018 states that:
The main types of data and information that evidence inequalities relate to:
• patient access to services, experience and health outcomes.30,31,32
Although Trusts are contracted to collect these data they have wide latitude 
in how this is done but are expected to seek out additional sources of information 
related to equality of care. Such sources should include published work as well 
as direct presentations. The guidance that is available on commissioning to 
reduce inequalities notes that local need is an essential factor to be aware of.33 
However, failure to collect and monitor information on patient ethnicity is 
widespread. In the Race Equality Service Review only 9 of 24 trusts collected 
such data. However, only 3 of the 15 who failed to collect the data admitted to 
doing so.34 Denial, as in this study on the underserving of South Asian patients, 
is the standard response to many requests to NHS organisations for information 
about ethnicity. Indeed a recent study of three Primary Care Trusts in the North 
of England found that:
Rather than being embedded within processes of understanding and responding 
to the health care needs of the local population, ethnic (and other) equalities 
work was generally constructed as a matter of legal compliance or, as one 
respondent explained, a nicety, not a necessity.35
30 NHS, ‘A refreshed Equality Delivery System for the NHS EDS2 Making Sure That 
Everyone Counts’ (2013) <england.nhs.uk/wp-content/uploads/2013/11/eds-nov131.pdf> 
accessed 14 May 2019.
31 NHS England, ‘NHS Standard Contracts 2016/17 Equality Impact Analysis’ (2016) 
<england.nhs.uk/wp-content/uploads/2016/03/nhs-std-con-eia.pdf> accessed 14 May 
2019.
32 NHS England, ‘NHS Standard Contracts 2017/18 and 2018/19 Equality Impact 
Analysis’ (2016) <england.nhs.uk/wp-content/uploads/2016/12/nhs-std-contract-eia-1718.
pdf > accessed 29 January 2017.
33 Dr Foster Intelligence, The Intelligent Board 2009: Commissioning to Reduce 
Inequalities (Dr Foster Intelligence 2009).
34 V Lyfar-Cisse, Race Equality Service Review (South East Coast BME Network 2008).
35 S Salway, G Mir D Turner, GT Ellison, L Carter and K Gerrish, ‘Obstacles to “Race 
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The Organisation Depends upon Complaints about Discrimination to 
Initiate Action
In 2015 the Health Select Committee has described the NHS complaints system in 
the following terms:
….Too many complaints are mishandled with people encountering poor 
communication or, at worst, a defensive and complicated system which results 
in a complete breakdown in trust and a failure to improve patient safety.36
The problem which this study has identified is that apparently none of the 
trusts have received any complaints indicating that their treatment policies were 
discriminatory. The complicated nature of the complaints system makes this not 
surprising. Indeed even the EHRC has had limited involvement with health care 
and unequal treatment related to protected characteristics. One of the few 
examples that has been reported was the formal agreement it made with NHS 
Tayside.37 Its purpose was to ensure that all deaf patients would have their 
communication needs met.
GENERAL COMMENTS
One of the roles of NICE is to ensure that effective medications are available to 
patients and the specific purpose of its Technology Appraisal Guidance is:
…….to reduce variations in practice across the country….38
These powers are set out in Regulation 7 of Statutory Instrument 2013 No. 259 
which states:
7 ((6) A relevant health body must comply with a technology appraisal 
recommendation.
Equality” in the English National Health Service: Insights from the Healthcare 
Commissioning Arena’ (2016) 152 Social Science & Medicine 102.
36 Health Select Committee, Complaints and Raising Concerns (HC 2014–2015, 350) para 3.
37 Equality and Human Rights Commission, ‘Section 23 Agreement between the 
Equality and Human Rights Commission and Tayside Health Board This Agreement 
dated 7 October 2014’ <nhstaysidecdn.scot.nhs.uk> accessed 11 April 2017.
38 NICE, ‘Charter’ (2013) <nice.org.uk/Media/Default/About/Who-we-are/NICE_
Charter.pdf> accessed 22 November 2016.
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Within its Quality Standard for Inflammatory Bowel Disease NICE also 
recognised:
Commissioners and providers should aim to achieve the quality standard in 
their local context, in light of their duties to have due regard to the need to 
eliminate unlawful discrimination.39
Monitor and CQC are charged with supervising the overall functioning of 
hospitals, but their inspections do not drill down into adherence to individual 
Guidance. However, in an obiter dicta in Rose v Thanet Clinical Commissioning 
Group, Mr Justice Jay said:
……The extent of the public law obligation is to have regard to the relevant 
NICE guideline and to provide clear reasons for any general policy that does 
not follow it…40
The NHS Litigation Authority has recognised the need for organisations to 
have mechanisms for monitoring implementation of NICE Guidelines.41 Where a 
Trust fails to do so, it is conceivable that a judicial review could require that 
organisation to reformulate its policies. Medical Directors were given responsibility 
for implementation and so failures might raise questions concerning their fitness 
to practice and lead to referral to the GMC. However, the question remains as to 
who would seek such a review or make such a referral.
The Public Sector Equality Duty identified in the Equality Act is the basis for 
the statement in the NHS Constitution that:
Legal duties require NHS England and each clinical commissioning group to 
have regard to the need to reduce inequalities in access to health services and 
the outcomes achieved for patients.42
39 NICE, ‘Inflammatory Bowel Disease’ (2015) <nice.org.uk/guidance/qs81> accessed 
14 May 2019.
40 [2014] EWHC 1182 (Admin).
41 NHS Litigation Authority, ‘An Organisation-Wide Document for the Dissemination, 
Implementation and Monitoring of NICE Guidance’ (2012) <nhsla.com/.../Document%20
for%20the%20Dissemination%20Implementation%> accessed 1 December 2016.
42 Department of Health, ‘Guidance: The NHS Constitution for England’ (2015) <gov.
uk/government/publications/the-nhs-constitution-for-england/the-nhs-constitution-for-
england> accessed 14 May 2019.
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Sections 212 and 213 of the Act make it clear that omission carries the same 
legal consequences as a requirement to perform a service. In 2013 Monitor was 
tasked with issuing Provider Licences to Trusts and among the conditions is:
... 4 (b) reducing inequalities between persons with respect to their ability to 
access those services….43
Monitor has been subsumed within NHS Improvement, but the organisation’s 
response was:
… Please note that NHS Improvement does not have a role in monitoring 
trusts’ compliance with equalities legislation.
Which COMMENT suggests it is unaware of its responsibilities under 4(b). 
Unfortunately, section 71 of the Health and Social Care Act (2012) provides no 
remedy to the ordinary citizen if Monitor fails in performance of its functions.
CQC considers its objectives are to:
… help to focus providers and commissioners on the importance of their 
responsibilities towards equality, diversity and human rights, and to 
improvement44
and ensure:
… an organisation provides services proportionately to different groups and 
their needs45
So it is disappointing that CQC is unable to readily identify any occasion when 
it has issued enforcement actions concerned with inequality in delivery of care 
related to ethnic diversity.
The Health and Social Care Act 2012 created Health and Social Welfare 
Boards to ensure local needs were met. However, such Boards lack formal powers 
43 Monitor, ‘The New NHS Provider Licence’ (2013) <gov.uk/government/uploads/
system/uploads/attachment_data/file/285008/ToPublishLicenceDoc14February.pdf> 
accessed 14 May 2019.
44 Care Quality Commission, ‘Equality and Human Rights Impact Assessment’ (EHRIA, 
2010) <cqc.org.uk/sites/default/files/documents/20100630_31_assessments_of_quality_
eia_pub_version.pdf> accessed 14 May 2019.
45 Ibid.
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to instruct CCGs or NHS Trusts and by building good relationships hope to 
influence decisions by these bodies. Their present role appears little more than that 
of a talking shop.
The question as to why Trusts and related organisations have failed to respond 
to the evidence of discrimination in the delivery of care is critical to any future 
actions to improve the situation. Interestingly in an earlier study of English 
Primary Care Trusts Salway et al. found that
……consideration of ethnicity was often treated as a matter of legal compliance 
rather than ntegral to understanding and meeting healthcare needs. Many 
managers and teams did not consider tackling ethnic healthcare inequities to 
be part-and-parcel of their job, lacked confidence and skills to do so, and 
questioned the legitimacy of such work…..46
The questioning of the legitimacy of such findings is common to this report. 
None of the respondent organisations identified any attempt by management to 
address these issues, often on the basis that they simply could not be true. Dilworth-
Anderson et al.47 (48) have suggested that in the US cultural interpretation of 
disease plays a central role with disparities in care being attributed to perceived 
rather than real differences and so legitimising a ‘Do nothing’ approach, because 
nothing needed to be done.
CONCLUSION
So where lies hope for a disadvantaged group of patients? Sadly the most likely 
route for individuals is through the tort of negligence. Clearly there will have been 
a breach of duty and but for that breach patients would have experienced a better 
quality of life through use of biologics and there is emerging data that their disease 
may have followed a different course. Any current hope that there will be 
management-driven changes or interventions by regulatory bodies seems forlorn.
46 Salway et al (n 37).
47 P Dilworth-Anderson, G Pierre and TS Hilliard, ‘Social Justice, Health Disparities, 
and Culture in the Care of the Elderly’ (2012) 152 Journal of Law & Medical Ethics 26.
